Format

Send to:

Choose Destination
See comment in PubMed Commons below
J Pain. 2015 Dec;16(12):1233-42. doi: 10.1016/j.jpain.2015.07.014. Epub 2015 Sep 16.

Cannabis for the Management of Pain: Assessment of Safety Study (COMPASS).

Author information

  • 1Department of Anesthesia, McGill University, Montreal, Quebec, Canada; Department of Family Medicine, McGill University, Montreal, Quebec, Canada. Electronic address: mark.ware@mcgill.ca.
  • 2Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, Quebec, Canada.
  • 3Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, Quebec, Canada; Centre for Clinical Epidemiology, Jewish General Hospital, Montreal, Quebec, Canada.
  • 4Department of Pediatrics, University of British Columbia; Child and Family Research Institute, Vancouver, British Columbia, Canada.

Abstract

Cannabis is widely used as a self-management strategy by patients with a wide range of symptoms and diseases including chronic non-cancer pain. The safety of cannabis use for medical purposes has not been systematically evaluated. We conducted a prospective cohort study to describe safety issues among individuals with chronic non-cancer pain. A standardized herbal cannabis product (12.5% tetrahydrocannabinol) was dispensed to eligible individuals for a 1-year period; controls were individuals with chronic pain from the same clinics who were not cannabis users. The primary outcome consisted of serious adverse events and non-serious adverse events. Secondary safety outcomes included pulmonary and neurocognitive function and standard hematology, biochemistry, renal, liver, and endocrine function. Secondary efficacy parameters included pain and other symptoms, mood, and quality of life. Two hundred and fifteen individuals with chronic pain were recruited to the cannabis group (141 current users and 58 ex-users) and 216 controls (chronic pain but no current cannabis use) from 7 clinics across Canada. The median daily cannabis dose was 2.5 g/d. There was no difference in risk of serious adverse events (adjusted incidence rate ratio = 1.08, 95% confidence interval = .57-2.04) between groups. Medical cannabis users were at increased risk of non-serious adverse events (adjusted incidence rate ratio = 1.73, 95% confidence interval = 1.41-2.13); most were mild to moderate. There were no differences in secondary safety assessments. Quality-controlled herbal cannabis, when used by patients with experience of cannabis use as part of a monitored treatment program over 1 year, appears to have a reasonable safety profile. Longer-term monitoring for functional outcomes is needed.

STUDY REGISTRATION:

The study was registered with www.controlled-trials.com (ISRCTN19449752).

PERSPECTIVE:

This study evaluated the safety of cannabis use by patients with chronic pain over 1 year. The study found that there was a higher rate of adverse events among cannabis users compared with controls but not for serious adverse events at an average dose of 2.5 g herbal cannabis per day.

Copyright © 2015 The Authors. Published by Elsevier Inc. All rights reserved.

KEYWORDS:

Cannabis; adverse events; chronic pain; cohort study; safety

PMID:
26385201
[PubMed - in process]
Free full text
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk